Summary
In Allergan v. Imprimis, the court concluded, at the summary judgment stage, that '[u]nder the plain language of the statute, anticipatory mass compounding of standardized drugs in a 503A facility without identified individual patients based on valid prescription orders is clearly violative of the FDCA.
Summary of this case from Hope Med. Enters. v. Fagron Compounding Servs.Opinion
Case No. 8:17-cv-01551-DOC-JDE
05-28-2019
ALLERGAN USA, INC., Plaintiff, v. IMPRIMIS PHARMACEUTICALS, INC., Defendant.
JUDGMENT
Pursuant to the jury's verdict, Dkt. No. 228, judgment is hereby entered in favor of plaintiff Allergan USA, Inc. and against defendant Imprimis Pharmaceuticals, Inc. in the amount of $48,500. Dated: May 28, 2019
/s/_________
Honorable David O. Carter
Judge United States District Court